Background/Aims: This study explored the correlation between hypertension and non-muscle myosin heavy chain 9 (MYH9) gene polymorphisms in Chinese chronic kidney disease (CKD) patients. Methods: This case-control study included 301 patients with CKD and 293 healthy controls. The E1 haplotype single nucleotide polymorphisms (SNPs) rs3752462 and rs4821480 were genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. The association between MYH9 polymorphisms and high systolic blood pressure (SBP ≥ 140 mmHg) susceptibility in CKD patients was analysed. Results: The cases and controls had similar genotype and allele distributions at rs3752462 and rs4821480. No GG genotype at rs4821480 was observed. Patients with SBP < 140 mmHg were more likely to have the CC genotype (17.1%) than patients with SBP ≥ 140 mmHg (4.3%) (P = 0.001). Creatinine clearance (OR = 0.99, 95% CI = 0.98-0.10, P = 0.01) was associated with SBP in patients with CKD. The risk of SBP ≥ 140 mmHg was 0.24-fold greater among patients with the CC genotype than among patients with the TT genotype (P = 0.002). Conclusion: The rs3752462 polymorphism of MYH9 is associated with SBP in patients with CKD. The T allele in the dominant model was associated with an elevated risk for high SBP.
Introduction
The MYH9 gene, which is located on chromosome 22 q12.3-13.2, has 40 exons that encode a protein of approximately 224,000 kDa. The protein is a non-muscle myosin heavy chain that dimerizes to form the motor domain of non-muscle myosin IIA, an important motor protein found in most cells of the body [1] . The MYH9 gene is expressed in fibroblasts, erythroblasts, and kidney cells [2] . Abnormal MYH9 expression, positioning, or function change leads to cytoskeleton damage, causing proteinuria, haematuria, or renal failure in some cases [3] .
MYH9 has also been shown to be a major susceptibility gene for end-stage renal disease (ESRD) according to genome-wide association studies (GWAS) of different nephropathies, including idiopathic focal segmental glomerulosclerosis, human immunodeficiency virus (HIV)-associated nephropathy, and hypertension. This association has also been demonstrated in various populations, ranging from African-Americans and Hispanic Americans to Europeans [4] [5] [6] [7] . Multiple common single nucleotide polymorphisms (SNPs) in MYH9 are associated with a greater risk for nondiabetic ESRD and are the primary factor contributing to the higher risk of ESRD that is observed in African Americans compared with European Americans [7] . Freedman et al. [8] found that mutations in MYH9 associated with African-American proteinuria caused by high blood pressure were associated with ESRD. The rs4821481 MYH9 gene locus was associated with hypertensive renal damage, and rs11912763 and rs1005570 were strongly associated with high blood pressure [9] . However, a study in a South African population of mixed ethnic groups showed that the association of rs575152 with CKD was present only in patients with diabetes [10] and not in Caucasians from the UK [11] . However, rs3752462 was associated with CKD in Spanish Caucasians [12] . Therefore, there is strong evidence of ethnic differences associated with MYH9 SNPs.
Hypertension is one of the most common complications of CKD. It is also a major risk factor for CKD and the development of ESRD [13] . A high systolic blood pressure (SBP) of > 120 mmHg has been shown to be directly related to the carotid intima-media thickness in patients with CKD. Furthermore, it is directly related to the probability of atherosclerosis development and cardiac events and the risk of mortality [14, 15] . A recent study found that the prevalence of isolated systolic hypertension (ISH) increased with advanced CKD stage [16] . When blood pressure was investigated in older adults in the community, SBP showed a strong association with rapidly declining kidney function [16] . SBP can be considered to be a strong predictor of ESRD and shows better predictive value than diastolic blood pressure (DBP) in CKD patients [17] .
Hypertension is the result of genetic and environmental interactions and, accordingly, is a polygenic multifactorial disease. A one-standard-deviation increase in the genetic risk score is associated with a 23% increase in the probability of hypertension development [18] . In patients with CKD, risk factors for hypertension include the renin-angiotensin system, endothelin, stimulating peptide, nitric oxide, and vasoactive substances such as renal enzyme factors. Several studies have shown that SNPs in genes related to these factors may influence the development of CKD [19] [20] [21] [22] [23] and hypertension in patients with CKD [24, 25] .
However, to our knowledge, there have been no studies of genetic variations or mutations of MYH9 and their association with hypertension in patients with CKD among Asians. We aimed to clarify the association between MYH9, the SNPs rs3752462 and rs4821480, and hypertension in CKD in a Chinese population. The results show that there was no difference in the distribution of these SNPs between the healthy control subjects and patients with CKD. There was a difference in the distribution of the genotype at rs3752462 in patients with CKD with and without hypertension, defined as SBP ≥ 140 mmHg. The results suggest that the CC genotype at rs3752462 confers a lower risk of concurrent high SBP than does the TT genotype in CKD patients.
Materials and Methods

Subjects
A total of 594 subjects, including 301 patients with CKD and 293 healthy controls, were enrolled in the present study.
The 301 CKD patients hospitalized in the First Affiliated Hospital of Baotou Medical College (Inner Mongolia, China) between May 2013 and November 2014 were included. Diagnosis of CKD was based on the Kidney Disease Outcomes Quality Initiative (K/DOQI) clinical practice guidelines for chronic kidney disease established by the National Kidney Foundation [26] . We used the EPI-CKD [26] formula to calculate the estimated glomerular filtration rate (eGFR) according to the CKD stage. The eGFRs for stage one, two, three, four, and five CKD are ≥ 90 mL/min, between 60 and 89 mL/min, between 30 and 59 mL/min, 15 to 29 mL/ min, and < 15 mL/min, respectively.
A total of 293 healthy controls undergoing physical examination in the First Affiliated Hospital of Baotou Medical College between May 2013 and November 2014 were included. The inclusion criteria were (1) no known disease and (2) blood pressure, urine examination and serum creatinine values within normal ranges.
Patients with CKD were also divided into two subgroups according to SBP (≥ 140 mmHg [27] and < 140 mmHg). All participant blood pressure measurements (both SBP and DBP) were performed in the morning on an empty stomach in a resting state without any medication. The measurement was obtained twice using a mercury sphygmomanometer with at least a 1-minute interval between tests.
Peripheral venous blood was obtained from the subjects on an empty stomach immediately after the subjects arose in the morning. A total of 2 mL was collected using EDTA-K2 and was stored at -40°C. The age, sex, body mass index (BMI), complications of diabetes mellitus, 24-hour urinary protein, haemoglobin, platelets, uric acid, serum albumin, cholesterol, triglycerides, aspartate aminotransferase, alanine aminotransferase, low-density lipoprotein, high-density lipoprotein, serum creatinine level, and CKD stage of the CKD patients were recorded.
The study protocol conformed to the Declaration of Helsinki and was approved by the Institutional Review Board of the hospital. Written informed consent was obtained from all participants.
DNA isolation and MYH9 gene polymorphism genotyping
Genomic DNA was extracted from 50 µL of peripheral venous blood collected in EDTA according to the Miller method [28] . The MYH9 gene polymorphisms were identified using the polymerase chain reactionrestriction fragment length polymorphism (PCR-RFLP) technique. The MYH9 gene sequence (NG_011884.1) was used to design primers and enzyme loci (Table 1) . Genomic DNA was used as a template for PCR amplification. The PCR reaction system utilized a CFX96 Touch TM Real-Time PCR Detection System (BioRad, California, USA) with a 12.5-µL reaction volume, including 2 µL of DNA template, 1.25 µL of 10 ×buffer, 0.25 µL of each forward and reverse primer (Table 1) , 0.25 µL of dNTPs, 0.5 µL of TaqMan PCR Master Mix (GoadGen, Beijing, China), and a volume of double-distilled water (ddH2O) necessary to reach a final volume of 12.5 µL. The PCR conditions included pre-denaturation at 94°C for 3 min, followed by 30 cycles of denaturation at 94°C for 35 s, annealing at 55°C for 45 s, extension at 72°C for 55 s, and extension at 72°C for 5 min.
The resulting DNA was digested with restriction endonucleases. RsaI and DraI (SBS Genetech Co., Ltd., Beijing, China) were used for rs3752462 and rs4821480, respectively. Ten microliters of PCR amplification product was digested with 0.5 μL of the corresponding restriction endonuclease. Each digestion product was then treated in a water bath at 37°C for 16 hours. To verify genotypes, the Chinese National Human Genome Center (Beijing, China) sequenced the amplified and digested DNA products (Fig. 1) . 
Statistical analyses
Statistical analyses were performed using SPSS 16.0 software (SPSS Inc., Chicago, IL, USA). Quantitative data are expressed as medians (min, max), and significant differences were assessed using the MannWhitney U test for independent samples. Categorical data are presented as frequencies and were analysed using the chi-square test or Fisher's exact test where appropriate. Gene and genotype frequencies were calculated according to the Hardy-Weinberg equilibrium principle. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated with a stepwise multivariate logistic regression analysis using SBP as a dependent variable. P < 0.05 was considered statistically significant.
Results
Characteristics of the subjects
The demographic, clinical, and biochemical parameters of each of the groups included in the study are presented in Table 2 . There were significant differences between the healthy control group (n = 293) and the CKD group (n = 301) with respect to gender, age, BMI, SBP, DBP, cholesterol, serum creatinine, and creatinine clearance (all P < 0.05). There were also significant differences between the CKD patient groups with SBP ≥ 140 mmHg (n = 184) and SBP < 140 mmHg (n = 117) with respect to gender, diabetes, 24-hour urinary protein excretion, triglycerides, serum creatinine, creatinine clearance, and CKD stage (all P < 0.05). 
Genotype and allele distributions of the MYH9 polymorphisms
There were no significant differences between the healthy control group and the CKD group in terms of genotype or allele polymorphisms at rs3752462 or rs4821480. The most common genotype was TT at the rs3752462 site, with prevalences of 46.8% in the healthy control group and 50.8% in the CKD group. The most common genotype was TT at the rs4821480 site, with prevalences of 99.3% in the healthy control group and 99.0% in the CKD group. However, the remaining 1% of subjects all had the GT genotype, and no subjects with the GG genotype were found.
The comparison of the genotype distributions at rs3752462 in the patients with CKD grouped according to SBP showed that there were significant differences (P = 0.00), but the distribution differences of the T and C alleles were not significantly different. Patients with a SBP < 140 mmHg were more likely to have the CC genotype (17.1%) than those with a SBP ≥ 140 mmHg (4.3%) (P = 0.00) ( Table 3) .
Multivariate logistic regression analysis
The multivariate analysis showed that gender (OR = 1.88, 95% CI 1.14-3.10, P = 0.01), diabetes mellitus (OR = 2.37, 95% CI 1.20-4.55, P = 0.01), CC genotype at rs3752462 (OR = 0.24, 95% CI 0.10-0.61, P = 0.002), and creatinine clearance (OR = 0.99, 95% CI 0.98-0.10, P = 0.01) were associated with SBP in patients with CKD. The results are presented in Table 4 .
The risk of SBP ≥ 140 mmHg in patients with the CC genotype was 0.24-fold greater than that in patients with the TT genotype (P = 0.002); therefore, the CC genotype was a protective factor. Table 2 . General clinical data for the different study groups rs3752462 and rs4821480, and hypertension in Chinese CKD patients. The results showed no difference in the distribution of the two SNPs between the healthy control subjects and patients with CKD. However, there was a difference in the distribution of the CC, CT, and TT genotypes at rs3752462 in patients with CKD with SBP ≥ 140 mmHg and SBP < 140 mmHg. The multivariate analysis showed that the CC genotype at rs3752462 was associated with a lower risk of concurrent high SBP than was the TT genotype in CKD patients. This result provides evidence that there is a genetic link between MYH9 and hypertension in patients with CKD in China. This result should be considered when evaluating the risk of developing ESRD.
Different populations have shown different results with respect to the association between MYH9 SNPs and CKD. Some studies suggest a link between the development of ESRD and hypertension [4] [5] [6] [7] [8] [9] 12] , while others suggest no association [11] or an association only in patients with CKD and diabetes [10] . In this study, MYH9, as well as the rs3752462 and rs4821480 SNPs, showed similar distributions between the healthy control group and the CKD patients. The alleles were also similarly distributed. This result is different from the results of a study in a Spanish population, where a T allele at rs3752462 was shown to be related to lower eGFR values [12] . This discrepancy is likely due to genetic differences between the study populations. We found that MYH9 SNP rs3752462 was involved in the susceptibility of CKD patients to hypertension. Multivariate logistic regression analysis Table 4 . Multivariate logistic regression analysis of MYH9 Polymorphisms at rs3752462 with SBP in the patients with CKD
Discussion
Hypertension, particularly that defined by a high SBP, is a common complication of CKD that causes a high risk of CKD progression to ESRD and mortality. The results from some populations suggest that MYH9 polymorphisms are associated with hypertension risk in patients with CKD [8] . The aim of this study was to investigate the association between MYH9, the SNPs Table 3 . Genotype and Allele distributions of MYH9 polymorphisms in the different study groups indicated that the CC genotype was a protective factor against higher SBP in patients with CKD. It also indicated that the mutation of a C allele to a T allele can lead to an SBP increase. The rs4821480 SNP was not observed in our study of Chinese subjects; this result is consistent with the findings of a prior report [4] . The TT genotype proportion (99%) was much higher than the TG genotype proportion (1%). Because the GG genotype was absent, this SNP was not investigated further in terms of a potential correlation with hypertension and CKD. The absence of this genotype may be attributable to characteristics of the MYH9 gene among Chinese individuals and may be related to ethnic differences.
This study has some limitations. The study sample was small, which limited the ability to determine the association between hypertension susceptibility and both MYH9 gene polymorphisms among CKD patients. However, to our knowledge, this is the first study to show such an association in a Chinese population. The background characteristics of the healthy control group were significantly different from those of the CKD group. A more closely matched population may reveal differences that were not found in this study. Second, two notable GWAS identified an association between the E1(GCCT) haplotype and its tagged SNPs (rs4821480, rs3752462, rs4821481, rs2032487), which are located in a region of the MYH9 gene that contains introns 12-23 and associated with a high risk of ESRD in AfricanAmericans [6, 7] . Only rs3752462 and rs4821480 were investigated in our study because HapMap data indicated that no variations of rs2032487 and rs4821481 in haplotype E1 have been reported in China. Because it was difficult to determine the causal SNP in the current GWAS, additional deep sequencing data may be needed. Third, we did not examine the relationship between MYH9 gene polymorphisms and hypertension in patients without CKD; therefore, such a relationship cannot be excluded. A limitation of the current study is that we did not collect samples from these patients. These types of samples will be collected and tested in a future association study. Finally, during the course of our study, some newly published studies reported that an adjacent gene, APOL1 (Apolipoprotein L1), was more significantly associated than was MYH9 with non-diabetic forms of CKD in African-Americans [29] [30] [31] [32] . Thus, to identify the association between hypertension and APOL1 in CKD, linkage disequilibrium may be further analysed using our study data. G1 and G2 in APOL1 appeared in HapMap populations observed in Yoruba but not in Chinese, Japanese, or European populations. Further research was difficult to conduct in the current study. Nevertheless, mutation screening of APOL1 in a CKD cohort will be needed in the future (Table 5) .
Conclusion
In conclusion, although no association was revealed between CKD and the MYH9 rs3752462 and rs4821480 SNPs, we confirmed that the T allele in the dominant model was associated with an excess risk for high BP in patients with CKD. This is the first time that an association of this nature has been revealed in a Chinese population.
Disclosure Statement
The authors declare that they have no actual or potential conflicts of interest.
